Hizentra referral forms and patient support
Download Hizentra referral forms and find additional resources to support your patients throughout their treatment journeys
The convenience of self-infused Hizentra—covered under the same benefit category as IVIg.†
For updated coverage and comprehensive support, call Hizentra ConnectSM
1-877-355-4447
Monday–Friday, 8 AM to 8 PM ET
*100% coverage for patients with Medicare Part B and a qualifying Medigap plan after Part B annual deductible is met.
†Coverage of IVIg when administered in a clinical setting.
‡Chart notes must be up to date and include diagnostic criteria.
D80 |
Immunodeficiency with predominantly antibody defects |
---|---|
D80.0* |
Hereditary hypogammaglobulinemia
Autosomal recessive agammaglobulinemia (Swiss type) |
D80.1 |
Nonfamilial hypogammaglobulinemia
Agammaglobulinemia with immunoglobulin-bearing B-lymphocytes |
D80.2* | Selective deficiency of immunoglobulin A [IgA] |
D80.3* | Selective deficiency of immunoglobulin G [IgG] subclasses |
D80.4* | Selective deficiency of immunoglobulin M [IgM] |
D80.5* | Immunodeficiency with increased immunoglobulin M [IgM] |
D80.6* | Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia |
D80.7* | Transient hypogammaglobulinemia of infancy |
D80.8 |
Other immunodeficiencies with predominantly antibody defects
Kappa light chain deficiency |
D80.9 | Immunodeficiency with predominantly antibody defects, unspecified |
D81 |
Combined immunodeficiencies |
D81.0* | Severe combined immunodeficiency [SCID] with reticular dysgenesis |
D81.1* | Severe combined immunodeficiency [SCID] with low T- and B-cell numbers |
D81.2* | Severe combined immunodeficiency [SCID] with low or normal B-cell numbers |
D81.31 | Severe combined immunodeficiency [SCID] due to adenosine deaminase deficiency |
D81.4 | Nezelof's syndrome |
D81.5* | Purine nucleoside phosphorylase [PNP] deficiency |
D81.6* |
Major histocompatibility complex class I deficiency
Bare lymphocyte syndrome |
D81.7* | Major histocompatibility complex class II deficiency |
D81.82* | Activated Phosphoinositide 3-kinase Delta Syndrome [APDS] |
D81.89* | Other combined immunodeficiencies |
D81.9* |
Combined immunodeficiency, unspecified
Severe combined immunodeficiency disorder [SCID] NOS |
D82 |
Immunodeficiency associated with other major defectsExcludes: ataxia telangiectasia [Louis-Bar] (G11.3) |
D82.0* |
Wiskott-Aldrich syndrome
Immunodeficiency with thrombocytopenia and eczema |
D82.1* |
Di George's Syndrome
Pharyngeal pouch syndrome |
D82.2 | Immunodeficiency with short-limbed stature |
D82.3 |
Immunodeficiency following hereditary defective response to Epstein-Barr virus
X-linked lymphoproliferative disease |
D82.4* | Hyperimmunoglobulin E [IgE] syndrome |
D82.8 | Immunodeficiency associated with other specified major defects |
D82.9 | Immunodeficiency associated with major defect, unspecified |
D83 |
Common variable immunodeficiency |
D83.0* | Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function |
D83.1* | Common variable immunodeficiency with predominant immunoregulatory T-cell disorders |
D83.2* | Common variable immunodeficiency with autoantibodies to B- or T-cells |
D83.8* | Other common variable immunodeficiencies |
D83.9* | Common variable immunodeficiency, unspecified |
D84 |
Immunodeficiency, unspecified |
D84.9 | Immunodeficiency, unspecified |
G11 |
Hereditary Ataxia |
G11.3* |
Cerebellar ataxia with defective DNA repair
Ataxia telangiectasia |
G61 |
Chronic inflammatory demyelinating polyneuritis |
G61.81* |
Chronic Inflammatory demyelinating polyneuritis
Chronic inflammatory demyelinating polyneuropathy Chronic inflammatory demyelinating polyradiculoneuropathy Polyneuropathy (multiple nerve disorder) Polyneuropathy, chronic inflammatory demyelinating Polyradiculoneuropathy, chronic inflammatory demyelinating Polyradiculoneuropathy, inflammatory demyelinating |
The following HCPCS codes describe supplies (including drugs) rendered by the billing provider. CMS publishes and maintains the HCPCS code set.
These codes are entered to paper claim form CMS-1500 in Field 24; or to electronic claim form ASC 837P in Loop 2400, Segment SV101-2, with the Qualifier "HC" entered to Segment SV101-1, unless otherwise directed by the payer.
Hizentra: Immune Globulin Subcutaneous (Human), 20% liquid3 |
|
HCPCS Code |
Description |
J1559 |
Injection, immune globulin (Hizentra), 100 mg |
Ready-to-use Hizentra vial sizes Certain payers may require the entry of NDC information to the claim form, as directed by the payer. |
||
Grams Protein |
Fill Size |
Carton NDC Number* |
1 g |
5 mL |
44206-0451-01 |
2 g |
10 mL |
44206-0452-02 |
4 g |
20 mL |
44206-0454-04 |
10 g |
50 mL |
44206-0455-10 |
Ready-to-use Hizentra prefilled syringe sizes Certain payers may require the entry of NDC information to the claim form, as directed by the payer. |
||
Grams Protein |
Fill Size |
Carton NDC Number* |
1 g |
5 mL |
44206-0456-21 |
2 g |
10 mL |
44206-0457-22 |
4 g |
20 mL |
44206-0458-24 |
10 g |
50 mL |
44206-0455-25 |
If the billing provider performs administration services in conjunction with a patient’s infusion, the following administration codes may be used to bill for this service if the service meets the requirements of the code description.
CPT Code2,4-6 |
Description |
96369 |
Subcutaneous injection for therapy or prophylaxis; initial, up to 1 hour, including pump setup and establishment of subcutaneous infusion site(s) |
96370 |
Each additional hour |
96371 |
Additional pump setup with establishment of new subcutaneous infusion site(s) |
S9338 |
Home infusion therapy, immunotherapy, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
G0089 |
Subcutaneous immunotherapy and other certain subcutaneous infusion drugs, initial encounter |
G0069 |
Subcutaneous immunotherapy and other certain subcutaneous infusion drugs, subsequent encounter |
Providers must be a qualified HIT supplier to bill for professional services. Section 1861(iii)(3)(C) of the Act defines a “home infusion drug” as a parenteral drug or biological administered intravenously, or subcutaneously for an administration period of 15 minutes or more, in the home of an individual through a pump that is an item of durable medical equipment (as defined in section 1861(n) of the Act). The professional visit G-code claim will recycle three times (with a 30-day look back period) for a total of 15 business days. After 15 business days, if no J-code claim is found in claims history, the G-code claim will be denied. |
The Medicare benefit for patients with primary immune deficiency or chronic inflammatory demyelinating polyneuropathy for subcutaneous immune globulin administered by DME MACs applies only to those products that are specifically labeled as subcutaneous administration products. Intravenous immune globulin products administered via the subcutaneous route are not covered by Medicare DME MACs (refer to Local Coverage Decision for External Pumps, effective 2/4/2011).
When the billing provider furnishes an external infusion pump for patient use, the following code may be used to bill for the pump if it meets the requirements of the code description.
External infusion pump |
|
HCPCS Code |
Description |
E0779 |
Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater |
E0779 is the only
reimbursable pump code for infusion of Hizentra under Medicare Part B.*
|
|
E0781 |
Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient |
E0791 |
Parenteral infusion pump, stationary, single or multichannel |
When the billing provider furnishes supplies for the patient's use with the external infusion pump, the following codes may be appropriate for the supplies if they meet the requirements of the code description and payer coverage policies. |
Professional services for drug infusion |
|
HCPCS Code |
Description |
G0069 |
Professional services for the administration of subcutaneous immunotherapy for each infusion drug administration calendar day in the individual's home, each 15 minutes |
External infusion pump supplies |
|
HCPCS Code |
Description |
K0552 |
Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each |
A4221 |
Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) |
A4222 |
Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) |
*For E0779 and K0455 pumps, either A4222 or K0552 may be billed, but not both. |
Modifier -JB for Medicare billing |
|
Medicare requires the addition of Modifier -JB (administered subcutaneously) to the HCPCS code for Hizentra (J1559) to confirm subcutaneous administration. Example: J1559-JB. Commercial and Medicaid plans may require the use of the JB modifier. If required, JB should also be added to the HCPCS code for the covered infusion pump (E0779) following the modifier that indicates whether the pump is being rented (RR) or purchased (NU). Example: E0779-RR-JB or E0779-NU-JB. Always check with the plan to see if the modifier code is required. |
ICD=International Classification of Diseases
HCPCS=Healthcare Common Procedure Coding System
CPT=Current Procedural Terminology
Download Hizentra referral forms and find additional resources to support your patients throughout their treatment journeys
More information about helping patients get started and stay on Hizentra may be found in our FAQs section